EndoStim, Inc., a St. Louis-based medical device company developing minimally-invasive interventional therapies to treat gastrointestinal and urological neuro-muscular disorders, has raised $6m in Series B equity financing.
The round was led by Santé Ventures, with participation from Prolog Ventures, Vectis Healthcare and Life Sciences Fund II and returning angel investors.
The new capital will be used to to continue clinical trials and pursue CE Mark and FDA approval for the company’s new treatment for sphincter related disorders such as Gastroesophageal Reflux Disease (GERD) and Urinary Urge Incontinence, aimed at restoring physiological function through neurostimulation.
In conjunction with the new financing, Santé Ventures Managing Director, Doug French, Voyent Partners member, Fred Goad, and James S. McDonnell Foundation Director, Jeff McDonnell, will join EndoStim’s board of directors.
FinSMEs
19/07/2010